← Research

The Case for More Aggressive Masking in Psychedelic Trials

Yang KH, Heifets BD, Krystal A, et al. — UCSF / Stanford University / UC San Diego

Published in JAMA Psychiatry

Correct guessing of treatment assignment now exceeds 90% in high-dose psilocybin trials, versus roughly 60% in ordinary antidepressant trials. UCSF's Josh Woolley and co-authors propose UMBRAA — Unidentifiable Multidrug Blinding with Reduced, Authorized Awareness — pairing carefully selected, already-approved drugs with limited disclosure to participants about which drugs they're getting, instead of a single inert or low-dose placebo. No trial has tested it yet; this is a proposed framework, not a result.

Read the Full Paper at JAMA Psychiatry